NCT04704661: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase of the study; Patients must have progressed on at least 1 line of anti-HER2 therapy; Patients with new or progressive brain metastases – active brain metastases or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required
Exclusions: Patients with previous treatment of an ATR inhibitor; Patients with clinically active central nervous system metastases, defined as untreated & symptomatic, or requiring therapy

Comments are closed.

Up ↑